Role and development of GLP-1 receptor agonists in the management of diabetes

References

• ElrickHStimmlerLHladCJ JrAraiYPlasma insulin response to oral and intravenous glucose administrationJ Clin Endocrinol Metab1964241076108214228531
   PubMed Web of Science ®Google Scholar
• McIntyreNHoldsworthCDTurnerDSIntestinal factors in the control of insulin secretionJ Clin Endocrinol Metab19652510131713245320560
   PubMed Web of Science ®Google Scholar
• PerleyMJKipnisDMPlasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjectsJ Clin Invest19674612195419626074000
   PubMed Web of Science ®Google Scholar
• BuffaRPolakJMPearseAGESolciaEGrimeliusLCapellaCIdentification of the Intestinal Cell Storing Gastric Inhibitory PeptideHistochemistry1975432492551097380
   PubMedGoogle Scholar
• OrskovCHolstJJKnuhtsenSBaldisseraFGPoulsenSSNielsenOVGlucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreasEndocrinology19861194146714753530719
   PubMed Web of Science ®Google Scholar
• TheodorakisMJCarlsonOMichopoulosSHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIPAm J Physiol Endocrinol Metab20062903E550E55916219666
   PubMed Web of Science ®Google Scholar
• EisseleRGokeRWillemerSGlucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and manEur J Clin Invest19922242832911499644
   PubMed Web of Science ®Google Scholar
• MeierJJNauckMAGlucagon-like peptide 1(GLP-1) in biology and pathologyDiabetes Metab Res Rev20052129111715759282
   PubMed Web of Science ®Google Scholar
• KrarupTSaurbreyNMoodyAJKuhlCMadsbadSEffect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitusMetabolism19873676776823298936
   PubMed Web of Science ®Google Scholar
• NauckMAHeimesaatMMOrskovCHolstJJEbertRCreutzfeldtWPreserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitusJ Clin Invest19939113013078423228
   PubMed Web of Science ®Google Scholar
• ElahiDMcAloon-DykeMFukagawaNKThe insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjectsRegul Pept14199451163748036284
   PubMedGoogle Scholar
• FeinleCChapmanIMWishartJHorowitzMPlasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese menPeptides20022381491149512182952
   PubMed Web of Science ®Google Scholar
• JangHJKokrashviliZTheodorakisMJGut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1Proc Natl Acad Sci U S A200710438150691507417724330
   PubMed Web of Science ®Google Scholar
• ElliottRMMorganLMTredgerJADeaconSWrightJMarksVGlucagon-like peptide-1 (7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patternsJ Endocrinol199313811591667852887
   PubMed Web of Science ®Google Scholar
• KimWEganJMThe role of incretins in glucose homeostasis and diabetes treatmentPharmacol Rev200860447051219074620
   PubMed Web of Science ®Google Scholar
• VollmerKHolstJJBallerBPredictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose toleranceDiabetes200857367868718057091
   PubMed Web of Science ®Google Scholar
• NauckMAHeimesaatMMBehleKEffects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteersJ Clin Endocrinol Metab20028731239124611889194
   PubMed Web of Science ®Google Scholar
• Toft-NielsenMBDamholtMBMadsbadSDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patientsJ Clin Endocrinol Metab20018683717372311502801
   PubMed Web of Science ®Google Scholar
• VilsbollTKrarupTDeaconCFMadsbadSHolstJJReduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patientsDiabetes200150360961311246881
   PubMed Web of Science ®Google Scholar
• KiefferTJMcIntoshCHPedersonRADegradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IVEndocrinology19951368358535967628397
   PubMed Web of Science ®Google Scholar
• Hupe-SodmannKMcGregorGPBridenbaughRCharacterisation of the processing by human neutral endopeptidase 24.11 of GLP-1 (7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptidesRegul Pept19955831491568577927
   PubMedGoogle Scholar
• MeierJJNauckMAKranzDSecretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjectsDiabetes200453365466214988249
   PubMed Web of Science ®Google Scholar
• HansenLDeaconCFOrskovCHolstJJGlucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestineEndocrinology1999140115356536310537167
   PubMed Web of Science ®Google Scholar
• Ruiz-GrandeCAlarconCAlcantaraARenal catabolism of truncated glucagon-like peptide 1Horm Metab Res199325126126168119664
   PubMed Web of Science ®Google Scholar
• ThorensBPorretABuhlerLDengSPMorelPWidmannCCloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptorDiabetes19934211167816828405712
   PubMed Web of Science ®Google Scholar
• KiefferTJHabenerJFThe glucagon-like peptidesEndocr Rev199920687691310605628
   PubMed Web of Science ®Google Scholar
• KjemsLLHolstJJVolundAMadsbadSThe influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjectsDiabetes200352238038612540611
   PubMed Web of Science ®Google Scholar
• RachmanJGribbleFMBarrowBALevyJCBuchananKDTurnerRCNormalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7–36) amide in patients with NIDDMDiabetes19964511152415308866556
   PubMed Web of Science ®Google Scholar
• ZanderMMadsbadSMadsenJLHolstJJEffect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group studyLancet2002359930982483011897280
   PubMed Web of Science ®Google Scholar
• MeneillyGSGreigNTildesleyHHabenerJFEganJMElahiDEffects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetesDiabetes Care200326102835284114514588
   PubMed Web of Science ®Google Scholar
• MeneillyGSVeldhuisJDElahiDDeconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetesJ Clin Endocrinol Metab200590116251625616091500
   PubMed Web of Science ®Google Scholar
• NauckMAKleineNOrskovCHolstJJWillmsBCreutzfeldtWNormalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patientsDiabetologia19933687417448405741
   PubMed Web of Science ®Google Scholar
• MeierJJGallwitzBSalmenSNormalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetesJ Clin Endocrinol Metab20038862719272512788879
   PubMed Web of Science ®Google Scholar
• VerdichCFlintAGutzwillerJPA meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humansJ Clin Endocrinol Metab20018694382438911549680
   PubMed Web of Science ®Google Scholar
• NaslundEGutniakMSkogarSRossnerSHellstromPMGlucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese menAm J Clin Nutr19986835255309734726
   PubMed Web of Science ®Google Scholar
• BrubakerPLDruckerDJMinireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous systemEndocrinology200414562653265915044356
   PubMed Web of Science ®Google Scholar
• EganJMBulottaAHuiHPerfettiRGLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cellsDiabetes Metab Res Rev200319211512312673779
   PubMed Web of Science ®Google Scholar
• ByrneMMGliemKWankUGlucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose toleranceDiabetes1998478125912659703326
   PubMed Web of Science ®Google Scholar
• MigoyaEMMillerJLarsonPSitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrationsDiabetes200756S1A74
   Google Scholar
• GreenBDGaultVAO’HarteFPFlattPRStructurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agentsCurr Pharm Des200410293651366215579061
   PubMed Web of Science ®Google Scholar
• KoltermanOGKimDDShenLPharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitusAm J Health Syst Pharm200562217318115700891
   PubMed Web of Science ®Google Scholar
• SimonsenLHolstJJDeaconCFExendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigsDiabetologia200649470671216447056
   PubMed Web of Science ®Google Scholar
• BuseJBHenryRRHanJKimDDFinemanMSBaronADEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes Care200427112628263515504997
   PubMed Web of Science ®Google Scholar
• DeFronzoRARatnerREHanJKimDDFinemanMSBaronADEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care20052851092110015855572
   PubMed Web of Science ®Google Scholar
• KendallDMRiddleMCRosenstockJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDiabetes Care20052851083109115855571
   PubMed Web of Science ®Google Scholar
• KlonoffDCBuseJBNielsenLLExenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurr Med Res Opin200824127528618053320
   PubMed Web of Science ®Google Scholar
• ZinmanBHoogwerfBJDuran GarciaSThe effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med2007146747748517404349
   PubMed Web of Science ®Google Scholar
• HeineRJVan GaalLFJohnsDMihmMJWidelMHBrodowsRGExenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med2005143855956916230722
   PubMed Web of Science ®Google Scholar
• NauckMAMeiningerGShengDTerranellaLSteinPPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trialDiabetes Obes Metab20079219420517300595
   PubMed Web of Science ®Google Scholar
• MorettoTJMiltonDRRidgeTDEfficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group studyClin Ther20083081448146018803987
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CompanyAmylin, Lilly Update on FDA Review of Byetta (exenatide) Injection Monotherapy Submission2008Accessed February 17, 2009 Available from: http://newsroom.lilly.com/releasedetail.cfm?releaseid=352884
   Google Scholar
• AmoriRELauJPittasAGEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysisJAMA2007298219420617622601
   PubMed Web of Science ®Google Scholar
• BainSCStephensJWExenatide and pancreatitis: an updateExpert Opin Drug Saf20087664364418983211
   PubMed Web of Science ®Google Scholar
• FehseFTrautmannMHolstJJExenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetesJ Clin Endocrinol Metab200590115991599716144950
   PubMed Web of Science ®Google Scholar
• MariANielsenLLNanayakkaraNDeFronzoRAFerranniniEHalsethAMathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylureaHorm Metab Res2006381283884417163361
   PubMed Web of Science ®Google Scholar
• BunckMCDiamantMCornerAOne-year treatment with exenatide improves beta-cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: A randomized, controlled trialDiabetes Care2009 Feb 5 Epub ahead of print
   Web of Science ®Google Scholar
• KnudsenLBKnudsenSMWilkenMPlasma protein binding of NN2211, a long-acting derivative of GLP-1, is important for its efficacyDiabetes200352Suppl 1A321A322
   Google Scholar
• KnudsenLBNielsenPFHuusfeldtPOPotent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administrationJ Med Chem20004391664166910794683
   PubMed Web of Science ®Google Scholar
• AgersoHJensenLBElbrondBRolanPZdravkovicMThe pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy menDiabetologia200245219520211935150
   PubMed Web of Science ®Google Scholar
• GarberAHenryRRatnerRLiraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialLancet2009373966247348118819705
   PubMed Web of Science ®Google Scholar
• NauckMFridAHermansenKEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 studyDiabetes Care2009321849018931095
   PubMed Web of Science ®Google Scholar
• MarreMShawJBrandleMLiraglutide, a once-daily human GLP-1 analog, added to a sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes Abstract presented at San Francisco, CA American Diabetes Association 68th Scientific Sessions2008
   Google Scholar
• Russell-JonesDVaagASchmitzOSignificantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes Abstract presented at San Francisco, CA American Diabetes Association 68th Scientific Sessions June 6–10, 2008
   Google Scholar
• ChangAMJakobsenGSturisJThe GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single doseDiabetes20035271786179112829647
   PubMed Web of Science ®Google Scholar
• MariADegnKBrockBRungbyJFerranniniESchmitzOEffects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditionsDiabetes Care20073082032203317468345
   PubMed Web of Science ®Google Scholar
• DegnKBJuhlCBSturisJOne week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetesDiabetes20045351187119415111485
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet200837296451240125018782641
   PubMed Web of Science ®Google Scholar
• KimDMacConellLZhuangDEffects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetesDiabetes Care20073061487149317353504
   PubMed Web of Science ®Google Scholar
• Eli LillyEli Lilly Investment community Update December 112008Accessed on: March 10, 2009 Available from: http://files.shareholder.com/downloads/LLY/544477551x0x258459/5acdc123-b0e7-498c-ab5c-92c599f205f2/Eli%20Lilly%2012-11-08.pdf
   Google Scholar
• BaggioLLHuangQCaoXDruckerDJAn albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasisGastroenterology200813441137114718313669
   PubMed Web of Science ®Google Scholar
• ConjuChemPD-DAC^TM: Exendin-4 (CJC-1145-PC)2009Accessed February 7, 2009 Available from: http://www.conjuchem.com/
   Google Scholar
• GlaxoSmithKlineGSK initiates phase III programme for novel type 2 diabetes medication, Syncria^® (albiglutide) February 172009Accessed March 31, 2009 Available from: http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10025.htm
   Google Scholar
• Novo NordiskOnce-weekly GLP-1 analogue (NN9535)2009Accessed March 7, 2009 Available from: http://www.novonordisk.com/science/pipeline/rd_pipeline.asp?showid=10
   Google Scholar
• F-Hoffmann-La Roche LtdRoche moves investigational diabetes drug, Taspoglutide, into Phase III clinical trials June 102008Accessed March 28, 2009 Available from: http://www.roche.com/med-cor-2008-06-10-e.pdf
   Google Scholar
• Sanofi-Aventis New diabetes compound AVE0010 showed clear dose response results with once-a-day injection in phase IIb study June 72008Accessed March 28, 2009 Available from: http://se.sanofi-aventis.com/live/se/sv/layout.jsp?cnt=A920FF21-6EA2-42A0-80BE-E242E4D1E088
   Google Scholar
• Merrion PharmaceuticalsMerrion announces license agreement with Novo Nordisk to develop oral formulation of GLP-1 receptor agonist(s) January 162009Accessed January 16, 2009 Available from: http://www.merrionpharma.com/archive/Merrion_NN_GLP-1.pdf
   Google Scholar
• NauckMADuranSKimDA comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia200750225926717160407
   PubMed Web of Science ®Google Scholar